Development of chitosan lipid nanoparticles to alleviate the pharmacological activity of piperine in the management of cognitive deficit in diabetic rats

• Published in: Scientific reports Vol. 14; no. 1; pp. 8247 - 17
• Main Authors: Darwish, Asmaa Badawy, Mohsen, Amira Mohamed, ElShebiney, Shaimaa, Elgohary, Rania, Younis, Mostafa Mohamed
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 08.04.2024; Nature Publishing Group; Nature Portfolio
• Subjects: 631/154/152; 631/154/433; 631/154/53; BDNF; Biological activity; Chitosan; Chitosan lipid nanoparticles; Cognitive ability; Diabetes; Diabetes mellitus; Diabetic cognitive deficit model; Drug delivery; Humanities and Social Sciences; Inflammation; Metformin; multidisciplinary; Nanoparticles; Oxidative stress; Piperine; Science; Science (multidisciplinary); Spatial memory; Stearic acid; Tripolyphosphate; Y-maze; Zeta potential; Piperine; Chitosan lipid nanoparticles; Diabetic cognitive deficit model; BDNF; Y-maze; Spatial memory
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-024-58601-x

The aim of the present study was to prepare and evaluate Piperine (PP) loaded chitosan lipid nanoparticles (PP-CLNPs) to evaluate its biological activity alone or in combination with the antidiabetic drug Metformin (MET) in the management of cognitive deficit in diabetic rats. Piperine was successfully loaded on CLNPs prepared using chitosan, stearic acid, Tween 80 and Tripolyphosphate (TPP) at different concentrations. The developed CLNPs exhibited high entrapment efficiency that ranged from 85.12 to 97.41%, a particle size in the range of 59.56–414 nm and a negatively charged zeta potential values (− 20.1 to − 43.9 mV). In vitro release study revealed enhanced PP release from CLNPs compared to that from free PP suspensions for up to 24 h. In vivo studies revealed that treatment with the optimized PP-CLNPs formulation (F2) exerted a cognitive enhancing effect and ameliorated the oxidative stress associated with diabetes. PP-CLNPs acted as an effective bio-enhancer which increased the potency of metformin in protecting brain tissue from diabetes-induced neuroinflammation and memory deterioration. These results suggested that CLNPs could be a promising drug delivery system for encapsulating PP and thus can be used as an adjuvant therapy in the management of high-risk diabetic cognitive impairment conditions.